China Resources Sanjiu Medical & Pharmaceutical's 6.2 billion yuan acquisition of Tasly Pharmaceutical Group is gradually taking shape in the traditional Chinese medicine sector. | Speed read announcement

China Resources Sanjiu Medical & Pharmaceutical spent 6.2 billion yuan to acquire 28% of Tasly Pharmaceutical Group's shares, becoming the controlling shareholder of Tasly. This transaction is helpful for China Resources Sanjiu Medical & Pharmaceutical to accelerate the supplement of innovative traditional Chinese medicine pipelines, improve research and development capabilities of innovative drugs, establish a leading advantage in the traditional Chinese medicine field, and enable both sides to have a synergistic effect in the traditional Chinese medicine industry chain, in areas such as traditional Chinese medicinal materials cultivation, innovative research and development, intelligent manufacturing, and channel marketing.

cls.cnAug 4 22:50

After two years of state-owned enterprise acquisition, Henan Taloph Pharmaceutical Stock is becoming increasingly outward-looking in the traditional Chinese medicine industry. | Industry research series

① The company plans to use the brand awareness and high market share marketing system of its core product Shuanghuanglian Oral Liquid to enhance the overall sales growth of the entire oral liquid business; ② As the subsidiary Tongjuntang won the honorary title of China's time-honored brand, it provided an opportunity for Tailong Pharmaceutical to enter the field of traditional Chinese medicine health; ③ After the company was included as the main enterprise in the biomedical industry chain in Zhengzhou, the intensity of foreign investment also increased markedly.

cls.cnJun 30 22:00

Received investment from pharmaceutical companies such as Tiger and Tessile, Peger Biotech relaunches its IPO and bets on GLP-1 in the future

① Peger Biotech has one GLP-1 product, PB-119, which is in the NDA stage, and five other products under clinical and pre-clinical development; ② Since the core product has not yet been approved, Peger Biotech is still in a “three no” state with “no products, no revenue, no profit”.

cls.cnMar 5 11:31

Is performance returning to growth and stock prices still underestimated? Harbin Pharmaceutical Co., Ltd. was called out by investors for “market value management” | Direct impact on performance meetings

① Harbin Pharmaceutical Co., Ltd. handed over excellent performance results in the third quarter, but investors called for an increase in stock prices eight times at the performance meeting. ② Company director Lin Guoren said that the company attaches importance to market value management while strengthening investor relations management activities. ③ Investors are also concerned about issues such as collection, mycoplasma pneumonia drugs, and product layout in the field of old-age care.

cls.cnNov 9, 2023 19:42

Major company news: Cinda withdraws from Ant Consumer Finance's equity subscription; TSMC's annual capital expenditure will exceed 40 billion US dollars

The biggest deal in the gaming industry, Take-Two announced the acquisition of Xingjia. Apple will pay $60 billion to developers in 2021. BMW beat Mercedes-Benz to win the 2021 global luxury car sales title. Airbus aircraft deliveries have surpassed Boeing for the third year in a row. New Oriental laid off 60,000 employees in 2021.

全球企業動態Jan 17, 2022 07:17

Tianshili: the subsidiary Meigang Hydrochloride sustained release capsule obtained the drug registration certificate.

Tianshili: the subsidiary Meigang Hydrochloride sustained release capsule obtained the drug registration certificate.

新浪財經Dec 20, 2021 15:36